BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BioAge Labs, Inc.NASDAQ: BIOA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $20.41M rose 83.7% year over year, ahead of the +36.9% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Research & development amounted to 822.3% of revenue in FY2025.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +83.7% holds above the trailing-twelve-month pace of +36.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 73.97M USD
- Year-over-year change
- +25.3%
- 3-year CAGR
- +34.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.97M | +25.3% |
| FY2024 | 2024-12-31 | 59.04M | +74.2% |
| FY2023 | 2023-12-31 | 33.89M | +11.0% |
| FY2022 | 2022-12-31 | 30.52M | — |
Research & Development vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +36.9% is the 3rd highest of 9, against a peer median of -9.7%.
- Research & development amounts to 807.2% of revenue for BIOA, versus a peer median of 5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $159.57M USD | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $151.01M USD | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $83.27M USD | +36.9% | +34.3% | 807.2% |
| LTM Mar 2026 | $73.35M USD | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $66.19M USD | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $7.58M USD | — | +1.8% | 5.6% | |
| LTM Mar 2026 | CA$4.98M CAD | +35.4% | +1.4% | 1.6% | |
| LTM Mar 2026 | $2.25M USD | -8.0% | -34.3% | 5.4% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Peer median (excluding BIOA) | — | -9.7% | +1.6% | 5.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.